Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy

Table 3 Association between treatment response (PSA ≤0.2 ng/ml) at last follow-up and possibly interacting variables (logistic regression analysis, all patients)

Association between treatment response and	p-Value^a	p-Value^b
ADT at time of RT	0.104	0.131
PRE-RT PSA ≤/> 0.5 ng/ml	0.226	0.188
Gleason Score (6–7 vs. 8–9)	0.129	0.791
pT stage	0.104	0.195
pN stage	0.341	0.908
Surgical margins	0.833	0.609
PSA after RT ≤ 0.1 ng/ml	0.008	0.007
PSMA PET result (Negative or fossa recurrence only vs. lymph node recurrence)	0.623	0.999
PSMA PET result (positive vs. negative)	0.263	0.693
Dose escalation prostate fossa ≤66.6Gy vs. >66Gy	0.324	0.122
Dose escalation pelvic lymph nodes ≤50.4Gy vs. >50.4Gy	0.371	0.999
RT indication (biochemical recurrence vs. biochemical persistence)	0.026	0.211

PSA prostate specific antigen, ADT androgen deprivation therapy, PRE-RT PSA PSA pre-radiotherapy, RT radiotherapy
^aunivariate and ^bmultivariate binary logistic regression analysis
*p < 0.05 statistically significant

ISSN: 1748-717X